A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...

The spot, which prominently utilizes a cover of “Here Comes the Sun” by The Beatles, manages to balance a message of hope with the somber nature of Alzheimer’s.

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...

Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) ...

While the United States remains a major market due to advanced research and telemedicine adoption (CAGR: 4.5%), Asia-Pacific ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous ...

Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or "ARIA." This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

Overall, the FDA approval of Kisunla™ could serve as a catalyst for Eli Lilly's continued success in the pharmaceutical sector, and these insights may help investors make informed decisions regarding ...

Notably, 1.6% of those treated with Kisunla experienced serious ARIA events, with three cases leading to death. Despite further analyses in a subgroup of patients with no copies of the ApoE4 gene, ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.